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Abstract
Background: The goal of antiretroviral therapy (ART) is to suppress viral replication, reduce morbidity and
mortality, and improve quality of life (QoL). For resource-limited settings, the World Health Organization
recommends a first-line regimen of two-nucleoside reverse-transcriptase inhibitors and one non-nucleoside
transcriptase inhibitor (nevirapine (NVP) or efavirenz (EFV)). There are few data comparing the QoL impact of
NVP versus EFV. This study assessed the change in QoL and factors associated with QoL among HIV patients
receiving ART regimens based on EFV or NVP.
Methods: We enrolled 640 people with HIV eligible for ART who received regimens including either NVP or
EFV. QoL was assessed at baseline, three months and six months using Physical Health Summary (PHS) and
Mental Health Summary (MHS) scores and the Global Person Generated Index (GPGI). Data were analyzed
using generalized estimating equations, with ART regimen as the primary exposure, to identify associations
between patient and disease factors and QoL.
Results: QoL increased on ART. The mean QoL scores did not differ significantly for regimens based on NVP
versus EFV during follow-up for MHS and GPGI regardless of CD4 stratum and for PHS among patients with a CD4
count >250 cells/μL. The PHS-adjusted β coefficients for ART regimens based on EFV versus NVP by CD4 count
strata were as follows: −1.61 (95 % CI −2.74, −0.49) for CD4 count <100 cells/μL; 0.82 (0.22, 1.43) for CD4 count
101–250 cells/μL; and −1.33 (−5.66, 3.00) for CD4 count >250 cells/μL. The corresponding MHS-adjusted β
coefficients were as follows: −0.39 (−1.40, 0.62) for CD4 < 100 cells/μL; 0.16 (−0.66, 0.98) for CD4 count 101–250
cells/μL; and −0.75 (−2.01, 0.51) for CD4 count >250 cells/μL. The GPGI-adjusted odds ratios for EFV versus NVP
were 0.51 (0.25, 1.04) for CD4 count <100 cells/μL, 0.98 (0.60, 1.58) for CD4 count 101–250 cells/μL, 1.39 (0.66, 2.90)
for CD4 > 250 cells/μL. QoL improved among patients on EFV over the 6-month follow-up period (MHS p < 0.001;
PHS p = 0.04, p = 0.028). Overall, patients with depression (PHS p < 0.001; GPGI p < 0.001) had lower scores and
women had lower MHS (on NVP, p = 0.001). Other factors associated with lower QoL included alcohol use, low
education level and advanced HIV disease.
Conclusions: ART improves QoL. The results support use of either NVP or EFV. Patients initiating ART should be
assessed for depression and managed appropriately. Women may require extra support to improve their QoL.
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Background
The World Health Organization (WHO) recommen-
dation for combination antiretroviral therapy (ART)
for HIV is two-nucleoside reverse-transcriptase inhib-
itors (zidovudine (AZT)/abacavir plus lamivudine
(3TC) or nucleotide tenofovir (TDF) plus 3TC) and a
non-nucleoside reverse-transcriptase inhibitor: efavir-
enz (EFV) or nevirapine (NVP) [1]. Uganda adopted
these guidelines, and regimens based on EFV or
NVP are used for first-line treatment [2]. Although
EFV and NVP have comparable clinical and viro-
logical efficacy [3–5], there are several differences be-
tween the regimens in terms of other clinical
outcomes and patient quality of life (QoL). EFV was
reported to produce stronger virological responses
than EFV among Ugandan patients receiving a first-
line ART regimen [6]. Furthermore, a systematic re-
view reported that an EFV-based first-line regimen
was less likely to lead to virological failure than a
NVP-based regimen [7].
The majority of clinical studies have focused on the
immunological and virological outcomes associated with
EFV and NVP. However, with the availability of ART,
there is no doubt that survival has been improved. In
Uganda, HIV/AIDS patients reportedly now have a life
expectancy similar to that of the general population [8].
For this reason, and with the increased availability of dif-
ferent drugs, there is an increasing focus on QoL in
selecting a regimen [9]. Studies of QoL associated with
different ART regimens have had inconsistent results.
One study that assessed QoL among ART- naïve pa-
tients receiving AZT and didanosine with or without
NVP found better QoL among patients on two drugs.
However, there was a better clinical and virological out-
come with the triple therapy [10]. In a study among
virologically suppressed patients receiving a protease in-
hibitor that was replaced with EFV or NVP, sustained
viral suppression was reported for both drugs and both
groups reported significant improvement of QoL [11].
Casado et al. [12] reported no differences at baseline in
demographic and clinical variables between patients re-
ceiving AZT and 3TC with NVP or nelfinavir. In
addition, there were no differences in QoL scores after
12 months of therapy [12]. However, there was a trend
towards improved Physical Health Summary (PHS) and
Mental Health Summary (MHS) scores for patients on
NVP [12]. It was also reported that regimens containing
EFV and/or NVP led to a similar increase in QoL [4]. It
is critical to understand the QoL outcomes with the
current ART regimens used in resource-limited settings.
Other factors have been associated with PHS, including
baseline viral load concentration ≥100,000 copies/ml and
decline in plasma viral load. An increase in MHS has been
associated with a decline in viral load. The presence of an
adverse event during follow-up has also been associated
with declines in both the MHS and PHS [4]. Adherence to
ART has been reported to be associated with QoL. Pa-
tients with a record of 100 % adherence to therapy had
higher QoL scores after one year of therapy than those
with lower adherence (80 %), and those with adherence of
less than 80 % had the worst QoL scores [13]. Depression,
younger age and low adherence to therapy were reported
as predictors of virological failure at baseline among pa-
tients receiving regimens based on EFV and NVP [14].
Also, good QoL and depression scores were reported
among African patients receiving regimens based on EFV
or protease inhibitors [15].
In summary, studies suggest similar virologic and
clinical outcomes for regimens based on NVP or EFV,
but findings for QoL outcomes have been inconsist-
ent. With the increased access to ART in sub-Saharan
Africa, we need to ensure both good clinical out-
comes and optimal QoL. Research is needed to im-
prove understanding of the impact on QoL of
different treatment options. There is limited research
on the differences in QoL between the recommended
ART regimens and sparse data on the different fac-
tors associated with QoL in relation to ART regi-
mens. The aim of this study was to assess the effect
of either NVP or EFV based regimen on QoL the
other factors associated with QoL and these ART reg-
imens. Our findings will help to inform strategies to
optimize patient outcomes.
Methods
Study participants
We enrolled 640 patients from an outpatient HIV clinic
at the Ugandan National Referral Hospital between
April 2012 and December 2013. Patients were eligible
for the study if they were starting ART on the day of the
interview, were prescribed either of the following regi-
mens (TDF plus 3TC plus EFV/NVP or AZT plus 3TC
plus EFV/NVP), had a CD4 count <350 and were
18 years or older. Owing to the variable nature of CD4
count with time of day, fatigue, stress or infections [16],
patients with CD4 counts between 350 and 400 who
were ready to commence treatment were given ART.
Patients who did not consent, who were pregnant or
were too ill were excluded from the study. Owing to the
increased risk of hepatotoxicity, female patients with
CD4 > 250 cells/μL were started on an EFV regimen and
patients with a CD4 count <250 cells/μL and not co-
infected with tuberculosis were given a NVP-based regi-
men since it is cheaper than the EFV-based regimen.
Patients co-infected with hepatitis B, regardless of CD4
count, were also initiated on ART. Patients who had
had abnormal renal function tests were prescribed AZT
instead of TDF.
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Study design
This was a prospective cohort study to assess QoL and
factors associated with QoL among patients receiving
ART regimens based on NVP or EFV. Patients were
followed up for six months and were assessed at base-
line, three months and six months.
Ethical approval
The study was approved by Makerere University School of
Medicine, Research and Ethics Committee and the
Uganda National Council for Science and Technology. All
participants provided written, informed consent prior to
participation in the study.
Measures
Three patient-reported outcome measures were used.
First, the Medical Outcomes Study (MOS-HIV) Health
Survey was used to collect data on health-related QoL
(HRQoL). It is a disease-specific measure that has been
widely used [17]. MOS-HIV has been validated in
Uganda and is useful in measuring HRQoL in patients
with HIV/AIDS [18–20]. Second, the Global Person
Generated Index (GPGI) was used to assess global QoL,
as perceived by the participant. It has been validated in
Ethiopia, Thailand and Bangladesh and found to be reli-
able in measuring QoL [21]. Third, the Center for
Epidemiological Studies Depression scale (CES-D),
which has been successfully used in Ugandan settings
[22, 23], was used to measure depression. A 3-day self-
report was used to measure adherence and a score ≥95 %
was reported as adherent and <95 % reported as non-
adherent. We used a high cutoff of 95 % for adherent ver-
sus non-adherent because higher levels of adherence at
>95 % have been proved to achieve higher virological sup-
pression [24,25]. A study among Ugandan HIV patients re-
ported no significant differences in adherence levels while
comparing various adherence measures including three-
day self-report, visual analog scale, electronic medication
monitoring and unannounced pill count [26].
Independent variables
We collected data on sociodemographic characteristics
including sex, age, religion, monthly income, employ-
ment status, education level, marital status and social
behavioral characteristics (smoking, use of alcohol and
social support). Information was documented on clinical
characteristics such as WHO HIV stage, opportunistic
infection, diagnosis of clinical depression, toxicity that
warranted change of regimen, adherence to ART and
CD4 + T lymphocyte counts. Blood was drawn at base-
line and at the six-month visit for the CD4 cell count for
all patients. All patients were screened for depression
using CES-D at each of the three visits. We used a cutoff
score of at least 16 to suggest probable depression as
recommended by the author of CES-D [27].
Dependent variables
The MOS-HIV subscales were transformed into two
summary scores, PHS and MHS [28], normalized to a
T-score with a mean of 50 and standard deviation
(SD) of 10. GPGI is a subjective measure that enables
individuals to rate their own QoL. It is scored on a
scale of 0–100. A higher score indicates better global
QoL. Population scores for subjective measures such
as GPGI range between 60 and 80 [29]. As GPGI was
negatively skewed, with a cutoff tail at a score of 60,
we categorized a GPGI score of <60 as low and ≥60
as high [29].
Statistical analysis
To identify determinants of QoL among patients on an
EFV-based ART regimen and those receiving a NVP-
based regimen, we analyzed the two groups separately.
Descriptive statistics and frequencies were determined
for all sociodemographic, clinical and outcome variables.
For comparisons between the two groups we used chi-
square tests for categorical variables, and student’s
t-tests, Spearman’s correlation and Wilcoxon’s rank sum
tests for continuous variables. We determined effect size
as recommended by Cohen [30]. We compared the QoL
scores between the two groups over the follow-up period
unadjusted and adjusted for potential cofounders, with a
p value <0.20 for PHS and GPGI and a p value <0.10 for
MHS. The cutoff values were decided after the univari-
ate analysis but before building the multivariate analysis
model. We used different cutoffs in order to limit the
total number of variables in the model to not more than
10 and hence a stable model [31]. Owing to the differ-
ences in CD4 count at baseline among patients given ei-
ther EFV or NVP, we stratified by baseline CD4 count
(<100, 101–250 and >250) to understand better the dif-
ferences in QoL due to CD4 count and regimen. In each
stratum, we also tested for interaction between time and
ART regimen. Finally, we also tested for interaction be-
tween baseline CD4 count and time in the PHS, MHS
and GPGI models.
For the normally distributed outcome variables, we
used univariate linear regression with generalized esti-
mating equations (GEE) to identify factors associated
with PHS and MHS. All variables determined to be sig-
nificantly associated with PHS and MHS in univariate
models at p < 0.20 and p < 0.10, respectively, were con-
sidered in the final multivariate models. Sex and age
were considered as forced variables in the final multi-
variate models. Depression was not included in the
MHS model to avoid collinearity since MOS-HIV also
covered depression.
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We then ran two sets of models: one set with only the
forced variables, and the other set with the significant p
values (cutoff 0.20 for PHS and 0.10 for MHS). We ob-
served the standard errors for the forced variables and
found them to be approximately the same in the two
models; these were the final models without multi-
collinearity. To further test for collinearity, each of the
other variables was dropped from the model and we ob-
served changes in the standard errors for the forced vari-
ables. We used logistic regression with GEE to identify
demographic, behavioral and clinical characteristics as-
sociated with GPGI score at univariate and multivariate
analysis. All factors with p < 0.20 at univariate analysis
were included in the final multivariate model. The same
process was used to build the final multivariate model,
as was done for MHS and PHS. The value p < 0.05 was
used as a cutoff for the determinants of QoL at multivar-
iable analysis. We tested for interaction between ART
regimen and/or time and the significant factors at multi-
variate analysis. All statistical analyses were conducted
using Stata 12.1 (StataCorp 4905 Lakeway Drive college
station,Texas, USA).
Results
Six hundred and forty patients were enrolled in the study,
481 (70 %) were initiated on an EFV-based ART regimen
and 159 (30 %) on a NVP-based regimen. Of the total en-
rolled, 420 (66 %) were women. The mean CD4 change
(cells/μL) from baseline to six months was 182 (SD 148.5).
The patients on EFV had a higher mean CD4 change
(189.8, SD 7.2) than patients on a NVP regimen (160.2,
SD 11.5) p = 0.04 (Table 1). There were no significant dif-
ferences in adherence levels at three months and six
months by regimen type. At the three-month visit, 95 % of
patients on NVP had an adherence ≥95 % and 93 % of pa-
tients on EFV had an adherence score ≥95 % (p = 0.496).
By the six-month visit, 94 % of the patients on NVP had
an adherence ≥95 % and 93 % of the patients on the EFV
regimen had adherence ≥95 % (p = 0.922).
Among patients who received EFV, 18 (2.8 %) had
drug reactions that warranted a change of regimen, 10
(2.1 %) changed from EFV, eight (1.7 %) had hypersensi-
tivity skin reactions, and two (0.4 %) had severe dizzi-
ness. Of the eight patients (5 %) who changed from the
NVP-based regimen, two (1.3 % of all patients who had
received NVP) had Steven Johnson’s syndrome and the
rest (3.8 %) had a hypersensitivity rash. Other clinical
and sociodemographic characteristics are shown by ART
regimen in Table 1.
Regardless of ART regimen, there was a trend to-
wards an increase in the mean QoL scores from base-
line to the six-month visit; PHS and MHS were
normally distributed and presented as means and GPGI
was negatively skewed presented as medians (Table 2).
The improvement in QoL while on ART was further
confirmed by the effect sizes (change in score/SD; effect
size for PHS = 0.8/5.0 = 0.16, MHS = 0.8/4.8 = 0.17) and
the correlation for GPGI was 0.35. The effect sizes for
PHS and MHS were approximately 0.2, which is re-
ferred to as a “small effect” by Cohen, and a correlation
of 0.35 is equivalent to “a medium to large effect size”
[30]. There were no significant differences between
MHS and GPGI scores over six months between NVP
and EFV before and after adjusting for potential con-
founders as summarized in Table 3. However, there was
a decrease by 1.6 among patients on the EFV-based
regimen with CD4 < 100, and a protective effect of 0.82
among patients with CD4 counts between 101 and 250
on EFV. Similar to MHS and GPGI findings, there was
no difference in PHS for patients with CD4 count >250.
There was no evidence of interaction between ART
regimen and study visit in the PHS model, MHS model
and the GPGI model, regardless of the CD4 count
strata (Table 3). There was interaction between baseline
CD4 count and time in the PHS model (p = 0.003) and
borderline evidence with the GPGI model (p = 0.05) but
no evidence of interaction in the MHS model (p = 0.28).
Factors associated with PHS among patients receiving a
NVP-based ART regimen
Depression was the only factor significantly associated
with PHS among patients receiving a NVP-based regimen
at both univariate and multivariate analysis (adjusting for
study visit, sex, age, diagnosis of depression, income per
month, WHO stage, education level, baseline CD4 count
and opportunistic infection). People living with HIV/AIDS
(PLHA) receiving a NVP-based ART regimen with prob-
able depression (score ≥16) had on average 1.64 lower
PHS than those without depression (−1.64, 95 % confi-
dence interval [CI] −2.48 to −0.79; p < 0.001). There was
no evidence of interaction between depression and ART
regimen (p = 0.89).
Factors associated with PHS among patients receiving an
EFV-based ART regimen
The following factors were associated with PHS among
patients receiving an EFV-based ART regimen: study visit,
level of education, WHO stage and probable depression.
PHS improved from baseline to six months (p = 0.04). In
multivariate analysis (adjusting for study visit, sex, age,
diagnosis of depression, income per month, WHO stage,
education level, baseline CD4 count and opportunistic in-
fection), there was a 0.50 mean increase in PHS at six
months compared with baseline visit (95 % CI 0.06 to
0.93). Patents with higher education level had an overall
increase in PHS (p = 0.005). For example, patients with
tertiary education receiving an EFV-based regimen had a
2.16 mean increase in PHS compared with patients with a
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primary or no education (95 % CI 0.66 to 3.65). A pa-
tient with WHO stage 3&4 compared with those graded
as WHO stage 1&2 on average had a 0.86 lower PHS
(95 % CI −1.47 to −0.25). Depression was negatively as-
sociated with PHS among patients receiving EFV, and
PLHA with probable depression had a 1.67 lower mean
PHS than patients without depression (95 % CI −2.13
to −1.21). There was no evidence of interaction be-
tween WHO stage and ART regimen (p = 0.08), level of
education and ART regimen (p = 0.80), study visit and
ART regimen (p = 0.90) and depression and ART regi-
men (p = 0.88). There was evidence of interaction be-
tween WHO stage and time (p = 0.0002) and ART
regimen and baseline CD4 count (p = 0.003).
Factors associated with MHS among patients receiving a
NVP-based ART regimen
A woman on a NVP-based ART regimen compared with
a man had on average a 1.57 point lower MHS score
(95 % CI −2.40 to −0.73). Sex was the only factor signifi-
cantly associated with MHS among patients receiving a
NVP-based ART regimen. The factors adjusted for in
the multivariate model were sex, age, study visit, WHO
stage, marital status, social support, baseline CD4 count
and level of education.
Factors associated with MHS among patients receiving an
EFV-based ART regimen
Study visit was the only factor associated with MHS
among patients on an EFV-based ART regimen. There
was an improvement in MHS (p < 0.001) over time.
Patients had a mean increase of 1.04 MHS at the three-
month visit compared with the baseline visit (95 % CI
0.62 to 1.46), and a 0.7 point increase in MHS at the
six-month visit compared with the baseline visit (95 %
CI 0.33 to 1.17). There was no evidence of interaction
between the study visit and ART regimen (p = 0.90).
The factors adjusted for in the multivariate model were
sex, age, study visit, WHO stage, marital status, social
support, baseline CD4 count and level of education.
Table 1 Baseline sociodemographic and clinical characteristics
by ART regimen
Variable NVP based
regimen n (%)
EFV based
regimen n (%)
P value
Sex
Male 65 (41) 155 (32) 0.05
Female 94 (59) 326 (68)
Age 33.2 (7.68) 33.3 (8.00) 0.88
Education level
Primary or less 80 (50) 243 (50)
Secondary 63 (40) 192 (40) 0.98
Apprenticeship 12 (8) 32 (7)
Tertiary 4 (2) 14 (3)
Income per month
(USD)
<20 49 (31) 146 (30) 0.97
20–60 44 (28) 129 (27)
>60 66 (41) 206 (43)
Marital status
Married 103 (65) 275 (57)
Separated/divorced 36 (23) 124 (25) 0.30
Single 12 (7) 41 (9)
Widowed 8 (5) 41 (9)
Religion
Christian 124 (78) 397 (83) 0.03
Moslem 28 (18) 79 (16)
others 7 (4) 5 (1)
Employment status
Employed 137 (86) 386 (80) 0.09
Unemployed 22 (14) 95 (20)
Social support
Yes, family 126 (79) 405 (84) 0.18
Yes, others 29 (18) 60 (13)
None 4 (3) 16 (3)
Alcohol consumption
Yes 45 (28) 107 (22) 0.12
No 114 (72) 374 (78)
Smoking
Yes 6 (4) 18 (4) 0.57
No 153 (96) 96 (96)
Opportunisticinfection
Yes 52 (33) 153 (32) 0.83
No 107 (67) 328 (68)
WHO stage
1&2 135 (85) 378 (79)
3&4 24 (15) 103 (21) 0.08
Table 1 Baseline sociodemographic and clinical characteristics
by ART regimen (Continued)
CD4 count (cells/μL)
<100 48 (30) 68 (14) 1
101–250 93 (59) 96 (20) 0.08
>250 18 (11) 317 (66) <0.001
Overall <0.001
CD4 count (cells/μL) 166 (90, 218) 292 (208, 331) <0.001
Depression
No depression 103 (65) 310 (64)
Probable depression 56 (35) 171 (36) 0.94
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Factors associated with GPGI among patients receiving a
NVP-based ART regimen
For the GPGI score, depression was the only statistically
significant predictor in multivariate analysis. A patient
on a NVP regimen with probable depression (score ≥16)
had 0.31 lower odds of having a high GPGI score (95 %
CI 0.19 to 0.51) compared with a patient without de-
pression. There was no evidence of interaction between
ART regimen and depression (p = 0.48) and time and
depression (p = 0.16). The other variables in the multi-
variate model included sex, age, study visit, WHO stage,
education level, income per month, depression, employ-
ment status, alcohol use, social support and baseline
CD4 count.
Factors associated with GPGI among patients receiving an
EFV-based ART regimen
Several factors were associated with the GPGI score
among patients on an EFV-based regimen: study visit, al-
cohol consumption and depression. There was a signifi-
cant overall association of odds of a high GPGI score
over time from baseline visit to the six-month visit (p =
0.028). The odds of a high GPGI score at month six
compared with baseline were 1.34 (95 % CI 1.01 to
1.77). In addition, in patients taking an EFV-based ART
regimen, the odds of a high GPGI were 1.69 (95 % CI 1.18
to 2.42) for those who did not consume alcohol compared
with those who did. Patients with probable depression had
odds of 0.43 (95 % CI 0.33 to 0.55) for high GPGI score
compared with patients without depression. There was no
evidence of interaction between ART regimen and alcohol
consumption (p = 0.56) and ART regimen and time (p =
0.61). The following variables were included in the multi-
variate model: sex, age, study visit, WHO stage, education
level, income per month, depression, employment status,
alcohol use, social support, opportunistic infection and
baseline CD4 count.
In summary, depression and sex were associated with
QoL scores among patients on the NVP-based regimen
and study visit, probable depression, level of education,
WHO stage and alcohol use were associated with QoL
scores among patients on the EFV-based regimen.
Study visit was significant among patients receiving
EFV for all the QoL measures, and depression was sig-
nificant both for PHS and GPGI among patients receiv-
ing NVP. Table 4 summarizes all the covariates
included in the models.
Discussion
The objective of this study was to determine the factors
associated with QoL among HIV patients receiving a
first-line ART based on EFV or NVP, and to compare
the pattern of results for people on the two medication
regimens. There was a statistically significant improve-
ment in QoL scores while on ART, with small to
medium/large effect sizes observed. Effect sizes of this
magnitude have been interpreted as “a real effect of ART
on QoL scores that can be seen through a study to obvi-
ous effect” [32].
The differences in QoL scores were small compared
with what has been reported in other studies [4, 33].
However, the effect sizes observed (ranging between 0.23
and 0.37) were similar to those found by Cohen [30] and
are of a magnitude that has been shown to be related to
clinically important differences [34]. Of note, clinically
important differences are specific and may differ by
study population owing to different patient characteris-
tics such as severity of illness and social economic sta-
tus. Similarly, some studies in developed countries have
also reported an improvement in QoL while on ART
[4]. These patients were followed up for a period of
48 weeks. In addition, two longitudinal studies in devel-
oping countries have reported an improvement in QoL
while on ART [35, 36].
The above studies reported greater differences in
QoL than our study, possibly because of the longer
time of follow-up. In addition, the majority of partici-
pants in these studies were WHO stage 3&4 and likely
Table 2 Mean/median QoL scores at baseline, month 3 and month 6 visits
QoL summary score Baseline visit Month 3 visit Month 6 visit Change
from
baseline to
month 6
(SD/
correlation)
p value
Mean (SD) or median (IQR) Mean (SD) or median (IQR) Mean (SD) or median (IQR)
PHS 46.5 (4.6) 47.1 (3.9) 47.3 (3.8) 0.8 (5.0)
p = 0.0036
MHS 46.4 (4.5) 47.4 (3.5) 47.2 (3.3) 0.8 (4.8)
p = 0.0002
GPGI 71.7 (55, 85) 71.67 (57, 85) 73.3 (60,87) r = 0.35
p < 0.001
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to have greater changes in QoL, whereas in our study
the majority of patients were stage 1&2 and followed
up for only six months. These changes would be more
comparable to our findings if the effect sizes had been
reported. The interaction between baseline CD4 count
and time indicates that PHS may change with time
while on ART in relation to baseline CD4 count. The
borderline significant interaction term between CD4
count and GPGI and lack of evidence for interaction
between CD4 count and MHS show that mental health
and global QoL may not be dependent on CD4 changes
with time. Further to this, there were no significant dif-
ferences in change in MHS and GPGI QoL scores over
time when comparing the EFV and NVP regimens. Pa-
tients with CD4 count <100 cells/μL and on EFV had a
decrease in PHS. Those with a CD4 count between 101
and 250 cells/μL had an improvement in PHS; however,
there was also no difference in PHS between EFV and
Table 4 Variables included in the multivariate models
PHS model MHS model GPGI model
Sex Sex Sex
Age Age Age
Study visit Study visit Study visit
Baseline CD4 Baseline CD4 Baseline CD4
WHO stage WHO stage WHO stage
Depression - Depression
Income per month - Income per month
Level of education Level of education Level of education
Opportunistic infection - Opportunistic infection
- Marital status -
- Social status Social status
- - Employment status
- - Alcohol use
Table 3 Comparison of QoL scores between regimens based
on nevirapine or efavirenz over the follow-up period using GEE
QoL summary score β coefficient
(95 % CI)
β coefficient
(95 % CI)
OR (95 % CI) OR (95 % CI)
unadjusted Adjusted
PHS
CD4 count <100 cells/μl
NVP Ref Ref
EFV −1.61(−2.82 to −0.40) −1.61 (−2.74 to −0.49)a
P = 0.11d
CD4 count 101–250
cells/μl
NVP Ref Ref
EFV 0.17 (−0.70 to 1.05) 0.82 (0.22 to 1.43)a
P = 0.76d
CD4 count >250
cells/μl
NVP Ref Ref
EFV 0.97 (−0.35 to 2.30) −1.33 (−5.66 to 3.00)a
P = 0.90d
MHS
CD4 count <100 cells/μl
NVP Ref Ref
EFV −0.18 (−1.18 to 0.82) −0.39 (−1.40 to 0.62)b
P = 0.91d
CD4 count 101–250
cells/μl
NVP Ref
EFV −0.09 (−0.93 to 0.75) 0.16 (−0.66 to 0.98)b
P = 0.78d
CD4 count >250 cells/μl
NVP Ref Ref
EFV −0.84 (−2.09 to 0.42) −0.75 (−2.01 to 0.51)b
P = 0.65d
GPGI
CD4 count <100
cells/μlEFV
versus NVP
−0.59 (0.31 to 1.13) 0.51 (0.25 to1.04)c
P = 0.54d
CD4 count
101–250
cells/μl
EFV versus NVP 0.85 (0.54 to 1.33) 0.98 (0.60 to 1.56)c
Table 3 Comparison of QoL scores between regimens based
on nevirapine or efavirenz over the follow-up period using GEE
(Continued)
P = 0.08d
CD4 count >250 cells/μl
EFV versus NVP 1.30 (0.66 to 2.56) 1.39 (0.66 to 2.90)c
P = 0.08d
aadjusted for age, study visit, diagnosis of depression, income per month,
WHO stage, education level and opportunistic infection
badjusted for sex, age, study visit, WHO stage, marital status, social support
and level of education
cadjusted for sex, age, study visit, WHO stage, education level, income per
month, depression, employment status, alcohol use, social support and
opportunistic infection
dP value for interaction term (time*ART regimen)
Mwesigire et al. BMC Health Services Research  (2015) 15:292 Page 7 of 11
NVP regimens for patients with CD4 > 250 cells/μL. Gen-
erally, there was some improvement in MHS and PHS
from baseline to six months among patients on an EFV-
based regimen. There was no evidence of interaction
between regimen and time. EFV has been reported to im-
prove QoL in other settings [37]. Although there was
higher CD4 count recovery in the EFV group than the
NVP group, the EFV group had a higher baseline CD4
count, which a known predictor of CD4 recovery [38].
Thus, this change could not be attributed to the use of
EFV alone.
There were two severe reactions among patients on
the NVP-based regimen (two cases of Steven Johnson’s
syndrome). No severe neurological reactions to EFV were
reported (although two patients reported severe dizziness).
A higher proportion of NVP patients than EFV patients
required changing the regimen. Although we did not
examine the relationship between adverse events and
QoL, results from a qualitative sub study of this popula-
tion revealed minimal interference with QoL related to
side effects [39]. Furthermore, in a large randomized study
the side effects due to NVP did not affect the overall QoL
[4]. The improvement in QoL and less side effects for pa-
tients on the EFV regimen suggests that, where possible,
EFV may be preferred to NVP except in patients with a
very low CD4 count (<100 cells /μL).
To our knowledge, this study is the first to assess QoL
and factors associated with QoL among HIV patients re-
ceiving ART regimens based on EFV and NVP in sub-
Saharan Africa. The majority of studies have assessed
virological outcome and not QoL. For instance, EFV has
shown advantages over NVP in some studies, including
a lower risk of virological failure [3], greater efficacy
[40, 41], better adherence levels [41, 42], greater ease of
administration with once a day dosing, and less fre-
quent severe rash and hepatotoxicity [43]. Although
similar mortality rates for EFV and NVP were reported
in South African patients, those on EFV had higher
viral suppression after six months on therapy and were
less likely to change therapy [44]. Conversely, a NVP-
based regimen may yield lower HIV viral load (<1 copy/
mL) than an EFV-based regimen [45]. However, a sys-
tematic review recommended an EFV-based regimen as
a first-line therapy over NVP for HIV patients in
resource-limited settings owing to a lower risk of viro-
logical failure [43]. Nevertheless, in resource-limited
settings a similar virological outcome has been reported
for both EFV and NVP regimens despite the difference
in their adverse events [46].
In general, data are still limited regarding changes in
QoL related to ART regimens based on NVP or EFV.
Previous studies from developed countries have studied
QoL and ART regimens by comparing either NVP with
protease inhibitor or EFV with a protease inhibitor.
Among ART-experienced patients who were switched to
either EFV or protease inhibitor, patients who received
EFV reported a better QoL [37]. Another study with
ART-experienced patients who either received NVP or a
protease inhibitor reported no significant differences in
immunological changes (CD4 count) between the two
groups; however, the NVP group recorded a significantly
better improvement in QoL than the protease inhibitor
group [47]. One other study reported no differences in
QoL between patients on NVP and EFV among HIV pa-
tients naïve to ART in a multisite study in Asia, South
Africa, Australia, North America and Europe [4]. How-
ever, the majority of patients had a low CD4 count
(<200 cells/μL) and their regimen included stavudine.
The researchers also combined the results of the patients
who received NVP once daily with those who received it
twice a day [4].
Adherence to ART has been reported in other stud-
ies to be associated with QoL [13, 48]. A modest or no
association between adherence and QoL has also been
reported [49, 50]. Interestingly, both groups in this
study maintained high levels of adherence that were
not significantly different despite that the fact that the
EFV regimen is one combined pill once a day and the
NVP regimen used in this study had to be taken twice a
day. There was no significant association between QoL
and adherence with the two ART regimens. High levels
of adherence have been reported among Ugandans on
ART (91–100 % adherence scores) [26, 51]. It is pos-
sible that adherence fatigue develops later on, since our
study group had been on ART for only six months.
Among patients receiving a NVP-based ART regimen,
depression score was the only variable associated with
lower PHS and GPGI. Being female was associated with
lower MHS. WHO stage 3&4, low education level and
probable depression were associated with poor QoL in
this study among patients on EFV. Depression and alco-
hol use had a significant negative association with global
QoL among patients receiving an EFV-based regimen.
Depression was independent of time during the follow-
up period. Depression has been associated with poor
QoL in PLHA in other studies in both resource-limited
settings and developed countries [52–54]. In these stud-
ies, depression was associated with poor QoL, regardless
of ART regimen. In this study, PLHA with a low level of
education had poor QoL. Likewise, low education level
has also been associated with poor QoL in other studies
among patients receiving ART [19, 55, 56]. In this study,
regardless of ART regimen, women reported lower QoL
than men, and the same finding has also been reported
in another studies [57, 58]. Higher WHO stage has also
been reported to be a predictor of poor QoL among
HIV patients in Ethiopia [58]. The interaction between
WHO stage and time indicates that there are differences
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in recovery rates between the stages of HIV during the
follow-up time.
Limitations
This was not a randomized study but future studies
may build on these results. We recommend a randomized
study with women with a CD4 count of <250 cells/μL and
men with a CD4 count of <400/μL cells randomized to re-
ceive either NVP or EFV, with assessment of QoL as the
main outcome measure. Follow-up of six months is short
for a chronic illness and does not allow for assessment of
regimen efficacy or the proportion of patients who fail to
respond to therapy or switch to another regimen. We rec-
ommend studies with long follow-up and a large sample
of patients initiating ART to confirm the continuous im-
provement in QoL that occur when ART is initiated at
relatively high CD4 counts.
Conclusions
There was a trend towards an increase in mean and me-
dian QoL scores among patients on ART in this study, es-
pecially with the EFV-based regimen. The changes in
MHS and GPGI did not differ between patients using EFV
or NVP as the first-line treatment from baseline to six
months, and no difference was found in PHS for patients
with a CD4 count >250. Patients with a very low CD4
count (<100 cells/μL) have better PHS while on a NVP
regimen than an EFV regimen. By contrast, patients with
a CD4 count between 101 and 250 cells/μL have a better
PHS with an EFV regimen than a NVP regimen. Initiating
an ART regimen containing EFV at a higher CD4 count
led to improvement in QoL with time. NVP caused more
severe toxicity and a relatively higher incidence of toxic-
ities that warranted regimen change than EFV. This study
supports the WHO guidelines that were in effect at the
time of the study for resource-limited settings to initiate
ART at a higher CD4 count and to use either a regimen
based on NVP or EFV as a first-line therapy, albeit with a
preference to EFV.
Regardless of ART regimen, women initiating ART
may require more psychosocial support to improve their
mental health. All PLHA initiating ART should be
screened for depression and alcohol use, and appropriate
support should be given in order to improve or maintain
a high QoL.
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